152 related articles for article (PubMed ID: 37272892)
1. Design of novel DABO derivatives as HIV-1 RT inhibitors using molecular docking, molecular dynamics simulations and ADMET properties.
Zhang Y; Chen L; Wang Z; Zhu Y; Jiang H; Xu J; Xiong F
J Biomol Struct Dyn; 2024 May; 42(8):4196-4213. PubMed ID: 37272892
[TBL] [Abstract][Full Text] [Related]
2. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
Mao Y; Li Y; Hao M; Zhang S; Ai C
J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
Xu HR; Fu L; Zhan P; Liu XY
SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
[TBL] [Abstract][Full Text] [Related]
4. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
Cichero E; Fossa P
J Mol Model; 2012 Apr; 18(4):1573-82. PubMed ID: 21805124
[TBL] [Abstract][Full Text] [Related]
5. Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.
Liu J; He X; Zhang JZ
J Mol Model; 2014 Oct; 20(10):2451. PubMed ID: 25234608
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR, molecular docking, and molecular dynamics simulation of a novel thieno[3,4-d]pyrimidine inhibitor targeting human immunodeficiency virus type 1 reverse transcriptase.
Chu H; He QX; Wang JW; Deng YT; Wang J; Hu Y; Wang YQ; Lin ZH
J Biomol Struct Dyn; 2020 Sep; 38(15):4567-4578. PubMed ID: 31760877
[TBL] [Abstract][Full Text] [Related]
7.
Shirvani P; Fassihi A
J Biomol Struct Dyn; 2022 Aug; 40(13):5965-5982. PubMed ID: 33475043
[TBL] [Abstract][Full Text] [Related]
8. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
Vanangamudi M; Poongavanam V; Namasivayam V
Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
[TBL] [Abstract][Full Text] [Related]
10. Computational investigation of imidazo[2,1-b]oxazole derivatives as potential mutant BRAF kinase inhibitors: 3D-QSAR, molecular docking, molecular dynamics simulation, and ADMETox studies.
Boutalaka M; El Bahi S; Alaqarbeh M; El Alaouy MA; Koubi Y; Khatabi KE; Maghat H; Bouachrine M; Lakhlifi T
J Biomol Struct Dyn; 2024 Jul; 42(10):5268-5287. PubMed ID: 37424193
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR and docking studies on the HEPT derivatives of HIV-1 reverse transcriptase.
Latha RS; Vijayaraj R; Singam ER; Chitra K; Subramanian V
Chem Biol Drug Des; 2011 Sep; 78(3):418-26. PubMed ID: 21689378
[TBL] [Abstract][Full Text] [Related]
12. In silico discovery of potent and selective Janus kinase 3 (JAK3) inhibitors through 3D-QSAR, covalent docking, ADMET analysis, molecular dynamics simulations, and binding free energy of pyrazolopyrimidine derivatives.
Faris A; Hadni H; Ibrahim IM; Elhallaoui M
J Biomol Struct Dyn; 2024 Jun; 42(9):4817-4833. PubMed ID: 37338041
[TBL] [Abstract][Full Text] [Related]
13. Development of novel monoamine oxidase B (MAO-B) inhibitors by combined application of docking-based alignment, 3D-QSAR, ADMET prediction, molecular dynamics simulation, and MM_GBSA binding free energy.
El Aissouq A; Chedadi O; Bouachrine M; Ouammou A; Khalil F
J Biomol Struct Dyn; 2023 Jul; 41(10):4667-4680. PubMed ID: 35510607
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR, molecular docking, and molecular dynamics analysis of novel biphenyl-substituted pyridone derivatives as potent HIV-1 NNRTIs.
Jiang H; Li Y; Wang Z; Li S; Wu T; Xiong F
J Biomol Struct Dyn; 2023 Nov; ():1-16. PubMed ID: 37909494
[TBL] [Abstract][Full Text] [Related]
15. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Sivan SK; Manga V
J Mol Model; 2010 Jun; 16(6):1169-78. PubMed ID: 20013136
[TBL] [Abstract][Full Text] [Related]
17. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
Liu G; Wang W; Wan Y; Ju X; Gu S
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
[TBL] [Abstract][Full Text] [Related]
18. Design of novel dopamine D
Zhang C; Li Q; Meng L; Ren Y
J Biomol Struct Dyn; 2020 Feb; 38(3):860-885. PubMed ID: 30916624
[TBL] [Abstract][Full Text] [Related]
19. Molecular docking, QSAR and ADMET based mining of natural compounds against prime targets of HIV.
Vora J; Patel S; Sinha S; Sharma S; Srivastava A; Chhabria M; Shrivastava N
J Biomol Struct Dyn; 2019 Jan; 37(1):131-146. PubMed ID: 29268664
[TBL] [Abstract][Full Text] [Related]
20. 2D and 3D QSAR studies of diarylpyrimidine HIV-1 reverse transcriptase inhibitors.
Rebehmed J; Barbault F; Teixeira C; Maurel F
J Comput Aided Mol Des; 2008 Nov; 22(11):831-41. PubMed ID: 18506577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]